Clinical Trial

A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a Phase 1a/1b, open-label, dose escalation and expansion study to evaluate the safety and efficacy of CTIM-76 (study drug), a CLDN6-directed T cell-engaging bispecific antibody , in participants with platinum-refractory/resistant ovarian cancer (PRROC) and other advanced CLDN6-positive solid tumors (i.e., testicular and endometrial).
Protocol Amendment History 3 changes
notable Enrollment increased: 80 -> 156 participants 2026-06-03
notable Primary completion pushed: 2027-04-30 -> 2028-05-31 2026-06-03
minor Completion pushed: 2028-04-30 -> 2028-12-31 2026-06-03
Trial Details
NCT Number NCT06515613
Lead Sponsor Context Therapeutics Inc.
Conditions Platinum-resistant Ovarian Cancer, Testicular Cancer, Endometrial Cancer
Enrollment 156 participants
Start Date 2024-07-10
Primary Completion 2028-05-31 (estimated)
Study Completion 2028-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-06-16